Carmell Corporation is a biotechnology company dedicated to developing innovative regenerative medicine solutions that enhance healing and tissue repair. The company focuses on creating advanced therapeutic products that utilize its proprietary technology to harness the body’s innate healing processes. By addressing various medical needs in fields such as orthopedics, wound care, and sports medicine, Carmell aims to improve patient outcomes and provide pioneering treatment options that are safe and effective. The company's research and development efforts are centered on the commercialization of its products, with the goal of transforming the landscape of regenerative healthcare. Read More
Carmell Corp. (NASDAQ: CTCX) to acquire Elevai Skincare for $1.1 million with additional payments and assets, solidifying their bio-aesthetic skincare science.
NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc (NASDAQ: ELAB), a diversified holding company, and Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) and its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai”), to acquire the assets related to its skincare and haircare business (the “Acquisition”).
